Assoc. Prof. Petra Kovaříková, Ph.D.

Research interests

• Development of modern analytical and bioanalytical methods (HPLC/UHPLC-MS/MS) for determination of novel drugs in complex biological materials, stability of drugs/drug candidates in biological matrix
• Bioanalytical study on pharmacokinetics and biotransformation of novel thiosemicarbazone anti-cancer agents
• Bioanalysis, pharmacokinetics and bioactivation study of novel cardioprotective drugs
• Chromatographic analysis of polar compounds using alternative sorbents

Education and professional carrier

• Since 2012: associate professor of Pharmaceutical Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, thesis: High-performance liquid chromatography in the analysis of clinically used drugs and novel drug candidates
• 2004-2012: researcher at the Department of Pharmaceutical Chemistry and Drug Analysis, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague
• 2005-2011: researcher of the center “Research of new drugs“- Faculty of Pharmacy in Hradec Kralove, Charles University in Prague
• 2001-2006: PhD in Pharmaceutical Analysis - Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, thesis: Analytical evaluation of drugs and drug candidates using HPLC
• 1996-2001: MSc in Pharmacy - Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, thesis: The chromatographic methods in the analysis of drugs

Teaching experience

• Mentor of 1 post-doctoral research associate and 4 PhD students
• Supervisor of 1 Bc. and 30 MS.c theses
• Teaching of Pharmaceutical Analysis I and II. and Therapeutic Drug Monitoring 

Grants received (principal investigator)

• 2011-2013: Ministry of Health (NT12403-3/2011): “Pharmaceutical analysis, pharmacokinetics and biotransformation study of novel thiosemicarbazone anticancer agents”
• 2012: Ministry of Education (366/2012): “Innovation and development of instrumental laboratories for drug analysis”
• 2010-2012: Czech Science Foundation, post-doc. project (P206/10P439): “Modern bioanalytical approach to interdisciplinary investigation of bisdioxopiperazine cardioprotective agents”
• 2006: Ministry of Education (1319/2006): “Innovation of the subjects Drug Analysis and Therapeutic Drug
• 2005: Charles University (284/2006): “Pharmaceutical-analytical approach to evaluation of novel drug candidates from the group of iron chelators” of iron chelators”
• 2004: Charles University (395/2004): “Development of HPLC evaluation of novel drug candidates from the group of pyridoxal isonicotinoyl hydrazone analogues and the application to the analysis of biological materials”
• 2004: Ministry of Education (952/2004): “Stability study of pyridoxal isonicotinoyl hydrazone”

Other: Co-investigator-Czech Science Foundation (13-15008S) - New potential cardioprotective agents: study of structure-activity relationships in various types of myocardial injury, supervision of 3 student grants of Charles University, University Centre for Research of Toxic and Protective Effects of Drugs on Cardiovascular System

Professional membership

• Czech Society of Mass Spectrometry

Cooperation

• Assoc. Prof. PharmDr. Tomáš Šimůnek, Ph.D. -  In vitro investigation of bioactivation of cardioprotective agents
• PharmDr. Jaroslav Roh, Ph.D., Assoc. Prof. PharmDr. Kateřina Vávrová, Ph.D.   – Chemical synthesis of metabolites

• Assoc. Prof. PharmDr. Martin Štěrba, Ph.D. -  Pharmacokinetics and bioactivation of cardioprotective agents
• Prof. MuDr. Stanislav Mičuda, Ph.D.- Pharmacokinetics of thiosemicarbazone anticancer drugs

• Prof. Des R. Richardson -  Development of novel thiosemicarbazone anticancer drugs  - pharmacokinetics and biotransformation study

• Assoc. Prof. Katherine J. Franz - Development of boronate prochelators

Publications

Author and co-author of 41 articles in international journals with IF; 390 citations (WoS; excluding self-citations); H-index: 14 (WoS)

• Sestak V., Roh J., Klepalova L., Kovarikova P. A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor, Journal of Pharmaceutical and Biomedical Analysis. 2016; 124: 365-73 (IF₂₀₁₅=3.169)
• Jansová H., Bureš J., Macháček M., Hašková P., Jirkovská A., Roh J., Wang Q., Franz K.J., Kovaříková P., Šimůnek T. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products, Toxicology. 2016; 350-352:15-24 (IF₂₀₁₅=3.817)
• Hrušková K., Potůčková E., Hergeselová T., Liptáková L., Hašková P., Mingas P., Kovaříková P., Šimůnek T., Vávrová K. Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications, European Journal of Medicinal Chemistry. 2016; 120:97-110 (IF₂₀₁₅=3.902)
• Tycova A., Vido M., Kovarikova P., Foret F. Interface-free capillary electrophoresis-mass spectrometry system with nanospray ionization-Analysis of dexrazoxane in blood plasma, Journal of Chromatography A. 2016; 1466:173-9. (IF₂₀₁₅=3.926)
• Lenčová-Popelová O., Jansová H., Jirkovský E., Bureš J., Jirkovská-Vávrová A., Mazurová Y., Reimerová P., Vostatková L., Adamcová M., Hroch M., Pokorná Z., Kovaříková P., Šimůnek T, Štěrba M. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings? Toxicology. 2016; 372:52-63. (IF₂₀₁₅=3.817)
• Hašková P., Jansová H., Bureš J., Macháček M., Jirkovská A., Franz K.J., Kovaříková P., Šimůnek T.Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury. Toxicology. 2016; 371:17-28. (IF₂₀₁₅=3.817)

• Šesták V., Stariat J., Cermanová J., Potůčková E., Chládek J., Roh J., Bureš J., Jansová H., Průša P., Stěrba M., Mičuda S., Šimůnek T., Kalinowski D. S., Richardson D.R., Kovaříková P. Novel and Potent Anti-Tumor and Anti-Metastatic Di-2-Pyridylketone Thiosemicarbazones Demonstrate Marked Differences in Pharmacology Between the First and Second Generation Lead Agents, Oncotarget. 2015; 6(40):42411-28 (IF₂₀₁₅=5.008)

• Potůčková E., Roh J., Macháček M., Sahni S., Stariat J., Šesták V., Jansová H., Hašková P., Jirkovská A., Vávrová K., Kovaříková P., Kalinowski D. S., Richardson D. R., Šimůnek T. In vitro characterization of the pharmacological properties of the anti-cancer chelator, Bp4eT, and ts phase I metabolites, PLoS ONE. 2015; 10(10): e0139929 (IF₂₀₁₅=3.057)

• Bureš J., Jansová H., Stariat J., Filipský T., Mladěnka P., Šimůnek T., Kučera R., Klimeš J., Wang Q., Franz K.J., Kovaříková P. LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH). Journal of Pharmaceutical and Biomedical Analysis. 2015; 105(1): 55-63. (IF₂₀₁₅= 3.169)

• Potůčková E., Hrušková K., Bureš J., Kovaříková P., Špirková I.A., Pravdíková K., Kolbabová L., Hergeselová T., Hašková .P, Jansová H, Macháček M., Jirkovská A., Richardson V., Lane D.J., Kalinowski D.S., Richardson D.R., Vávrová K., Šimůnek T. Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties. PLoS One. 2014, 9(11): e112059.  (IF₂₀₁₄= 3.232)

• Cermanova J., Kadova Z., Dolezelova E., Zagorova M., Safka V., Hroch M., Laho T., Holeckova M., Mokry J., Kovarikova P., Bures J., Sterba M., Micuda S. Deferoxamine but not dexrazoxane alleviates liver injury induced by endotoxemia in rats. Shock. 2014, 42(4):372-79. (IF₂₀₁₄= 3.045)

• Kučera R., Kovaříková P., Pasáková-Vrbatová .I, Slaninová J., Klimeš J. Zirconia--a stationary phase capable of the separation of polar markers of myocardial metabolism in hydrophilic interaction chromatography. Journal of Separation Science. 2014, 37(9-10):1089-93. (IF₂₀₁₃= 2.594)

• Stariat J., Suprunová V., Roh J., Šesták V., Eisner T., Filipský T., Mladěnka P., Nobilis M., Šimůnek T., Klimeš J., Kalinowski D.S., Richardson D.R., Kovaříková P. Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: Application to a pilot pharmacokinetic study in rats. Biomedical Chromatography. 2014; 28(5):621-9 (IF₂₀₁₃= 1.662)

• Stariat J., Kovaříková P., Kučera R., Klimeš J., Kalinowski D.S, Richardson D.R, Ketola R.A. Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry, Analytical and Bioanalytical Chemistry. 2013; 405(5):1651-61. (IF₂₀₁₃= 3.578)

• Kovaříková P., Pasaková-Vrbatová I., Vávrová A., Stariat J., Klimeš J., Simunek T. Development of LC–MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium, Journal of Pharmaceutical and Biomedical Analysis .2013; 76(1): 243-51. (IF₂₀₁₃= 2.829)

• Štěrba M., Popelová O., Vávrová A., Jirkovský E., Kovaříková P., Geršl V., Šimůnek T. Oxidative stress, redox signaling and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection, Antioxidants & Redox Signaling. 2013; 18(8): 899-929. (IF₂₀₁₃: 7.667)

• Macková E., Hrušková K., Bendová P., Vávrová A., Jansová H., Hašková P., Kovaříková P., Vávrová K., Šimůnek T. Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: Novel iron chelators with selective antiproliferative action. Chemico-Biological Interactions. 2012; 197: 69-79. (IF₂₀₁₁: 2.865)

• Stariat J., Šesták V., Vávrová K., Nobilis M., Kollárová Z., Klimeš J., Kalinowski D.S., Richardson D.R., Kovaříková P. LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT, Analytical and Bioanalytical Chemistry. 2012; 403(1): 309-321. (IF₂₀₁₁: 3.778)

• Vávrová K., Kovaříková P., Školová B., Líbalová M., Roh J., Čáp R., Holý A., Hrabálek A. Enhanced Topical and Transdermal Delivery of Antineoplastic and Antiviral Acyclic Nucleoside Phosphonate cPr-PMEDAP. Pharmaceutical Research. 2011; 28(12): 3105-3115.  (IF₂₀₁₀: 4.456)

• Hašková P., Koubková L., Vávrová A., Macková E., Hrušková K., Kovaříková P., Vávrová K., Šimůnek T. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity. Toxicology. 2011; 28(2-3): 122-131. (IF₂₀₁₁: 3.681)

• Kučera R., Kovaříková P., Klivický M., Klimeš J. The retention behaviour of polar compounds on zirconia based stationary phases under hydrophilic interaction liquid chromatography conditions, Journal of Chromatography A. 2011; 1218(39): 6981-6986. (IF₂₀₁₁: 4.531)

• Pasáková I., Gladziszová M., Charvátová J., Stariat J., Klimeš J., Kovaříková P. Use of different stationary phases for separation of isoniazid, its metabolites and vitamin B6 forms, Journal of Separation Science. 2011; 34(12): 1357-1365. (IF₂₀₁₁: 2.733)

• Hrušková K., Kovaříková P., Bendová P., Hašková P., Macková E., Stariat J., Vávrová A., Vávrová K., Šimůnek T. Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis, Chemical Research in Toxicology. 2011; 24(3): 290-302. (IF₂₀₁₁: 3.779)

• Hašková P., Kovaříková P., Koubková L., Vávrová A., Macková E., Šimůnek T. Iron chelation with salicylaldehyde isonicotinoyl hydrazone (SIH) protects against catecholamine autooxidation and cardiotoxicity, Free Radical Biology and Medicine. 2011; 50(4): 537-549. (IF₂₀₁₁: 5.423)

• Kovaříková P., Stariat J., Klimeš J., Hrušková K., Vávrová K. Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites - The cardioprotectant dexrazoxane as a model case, Journal of Chromatography A. 2011; 1218(3): 416-426. (IF₂₀₁₁: 4.531)

• Bendová P., Macková E., Hašková P., Vávrová A., Jirkovský E., Šterba M., Popelová O., Kalinowski D.S, Kovaříková P., Vávrová K., Richardson D.R, Šimůnek T. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury, Chemical Research in Toxicology. 2010; 23(6): 1105-1114. (IF₂₀₁₀: 4.140)

• Stariat J., Kovaříková P., Klimeš J., Kalinowski D.S., Richardson D.R. Development of an LC-MS/MS method for analysis of interconvertible Z/E Isomers of novel anti-cancer agent, Bp4eT, Analytical and Bioanalytical Chemistry. 2010; 397(1): 161-171. (IF₂₀₁₀: 3.841)

• Pasáková I., Kovaříková P., Kučera R., Klimeš J., Sochor J., Hrabálek A. Development and validation of an LC-ESI-MS ion-trap method for analysis of impurities in Transkarbam 12, a novel transdermal accelerant Chromatographia. 2009; 96(9-10): 977-983. (IF₂₀₀₉: 1.098)

• Novotný J., Kovaříková P., Novotný M., Janušová B., Hrabálek A., Vávrová K. Dimethylamino acid esters as biodegradable and reversible transdermal permeation enhancers: Effects of linking chain length, chirality and polyfluorination, Pharmaceutical Research. 2009; 26(4): 811 – 821. (IF₂₀₀₉: 3.933)

• Stariat J., Kovaříková P., Klimeš J., Lovejoy D.B., Kalinowski D.S., Richardson D.R. HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents, Journal of Chromatography B. 2009; 877(3): 316 – 322. (IF₂₀₀₉: 2.777)

• Kovaříková P., Vávrová K., Tomalová K., Schöngut M., Hrušková K., Hašková P. Klimeš J. HPLC-DAD and MS/MS analysis of novel drug candidates from the group of aromatic hydrazones revealing the presence of geometric isomers, Journal of Pharmaceutical and Biomedical Analysis. 2008; 48(2): 295 - 302. (IF₂₀₀₈: 2.629)

• Mrkvičková Z., Kovaříková P., Balíková S., Klimeš J. Determination of lipophilicity of novel potential antituberculotic agents using HPLC on monolithic stationary phase and theoretical calculations, Journal of Pharmaceutical and Biomedical Analysis. 2008; 48(2): 310 - 314. (IF₂₀₀₈: 2.629)

• Kovaříková P., Mrkvičková Z., Klimeš J. Investigation of the stability of aromatic hydrazones in plasma and related biological material, Journal of Pharmaceutical and Biomedical Analysis. 2008; 47(2): 360 – 370. (IF₂₀₀₈: 2.629)

• Mrkvičková Z., Kovaříková P., Klimeš J., Kalinowski D., Richardson D.R.  Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity, Journal of Pharmaceutical and Biomedical Analysis. 2007; 43(4):  1343 - 1351. (IF₂₀₀₇: 2.761)

• Mrkvičková Z., Kovaříková P., Klimeš J., Doležal M. Determination of the lipophilicity of potential antituberculotic compounds by RP-TLC, Journal of Planar Chromatography. 2006; 19(112): 422 - 426. (IF₂₀₀₆: 1.153)

• Kovaříková P., Klimeš J., Štěrba M., Popelová O., Geršl V., Poňka, P. HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study, Journal of Chromatography B. 2006; 838(2): 107 - 112. (IF₂₀₀₆: 2.647)

• Kovaříková P., Mokrý M., Klimeš J., Vávrová K. HPLC study on stability of pyridoxal isonicotinoyl hydrazone, Journal of Pharmaceutical and Biomedical Analysis. 2006; 40(1): 105 - 112. (IF₂₀₀₆: 2.032)

• Kovaříková P., Klimeš J., Štěrba M. Popelová O., Mokrý M., Geršl V., Poňka P. Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study, Journal of Separation Science. 2005; 28(12): 1300 - 1306. (IF₂₀₀₅: 1.829)

• Kovaříková P., Mokrý M., Klimeš J., Vávrová K. Chromatographic methods for the separation of biocompatible iron chelators from their synthetic precursors and iron-chelates.  Journal of Separation Science, 2004; 27(17-18): 1503 - 1510. (IF₂₀₀₄: 1.927)

• Kovaříková P., Klimeš J., Dohnal J., Tisovská L. HPLC study of glimepiride under hydrolytic stress conditions. Journal of Pharmaceutical and Biomedical Analysis, 2004; 36(1): 205 - 209. (IF₂₀₀₄: 1.509)

• Kovaříková P., Mokrý M., Klimeš J. Photochemical stability of nimesulide. Journal of Pharmaceutical and Biomedical Analysis, 2003; 31(4): 827 – 832. (IF₂₀₀₃: 1.425)